MAB21L4: A Potential Drug Target and Biomarker (G79919)

Target Name: MAB21L4

NCBI ID: G79919

MAB21L4

MAB21L4: A Potential Drug Target and Biomarker

MAB21L4 is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. Its unique structure and expression pattern have caught the attention of researchers due to its potential involvement in a variety of biological processes. While more research is needed to fully understand its role, MAB21L4 has emerged as a promising drug target and biomarker.

The MAB21L4 protein is a member of the MAB family of proteins, which are known for their ability to interact with bacterial toxins and toxins produced by some bacteria. MAB21L4 is characterized by its N-terminal and C-terminal regions, which contain a putative transmembrane domain and a cytoplasmic tail, respectively.

MAB21L4 has been shown to play a role in several biological processes, including inflammation, autophagy, and cell signaling. For example, MAB21L4 has been shown to promote the production of pro-inflammatory cytokines, such as TNF-浼?, IL-1灏?, and IFN-绾?, in human keratinocytes. Additionally, MAB21L4 has been shown to contribute to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, by promoting the formation of toxic cellular aggregates.

Given its unique structure and its involvement in several biological processes, MAB21L4 has potential as a drug target. One approach to targeting MAB21L4 is to use small molecules, such as inhibitors, to disrupt its activity. For example, a group of researchers have synthesized a small molecule inhibitor that targets MAB21L4 and has shown that it can reduce the production of pro-inflammatory cytokines in human keratinocytes.

Another approach to targeting MAB21L4 is to use antibodies to block its function. Researchers have shown that antibodies specific for MAB21L4 can effectively inhibit its activity and prevent the formation of toxic cellular aggregates in neurodegenerative diseases.

In addition to its potential as a drug target, MAB21L4 also has potential as a biomarker. Its unique expression pattern and its involvement in several biological processes make it an attractive candidate for diagnostic tests. For example, researchers have shown that MAB21L4 is expressed in the brains of individuals with Alzheimer's disease, and that its levels are decreased in individuals with Parkinson's disease.

Furthermore, MAB21L4 has been shown to play a role in the development of neurodegenerative diseases by promoting the formation of toxic cellular aggregates. Therefore, its levels can be used as a biomarker for tracking the progression of these diseases.

In conclusion, MAB21L4 is a protein that has caught the attention of researchers due to its unique structure and expression pattern. While more research is needed to fully understand its role, MAB21L4 has potential as a drug target and biomarker. The development of small molecules and antibodies that can inhibit or detect MAB21L4 activity may lead to new treatments and therapies for a variety of neurodegenerative diseases.

Protein Name: Mab-21 Like 4

The "MAB21L4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAB21L4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets